Skip to content

Study · Case report or series · n = 1 · 2024

2 results

Liraglutide-associated depression in a patient with type 2 diabetes: A case report and discussion.

He Y, Liang F, Wang Y, Wei Y, Ma T

Medicine1 May 2024Cited by 6 (Europe PMC)

PMID38701264 (opens in a new tab)DOI10.1097/md.0000000000037928 (opens in a new tab)PepBankPUB-38701264
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

BackgroundGlucagon-like peptide-1 receptor agonists (GLP-1RAs) like liraglutide are primarily used for managing blood sugar levels in type 2 diabetes and aiding weight loss. Typically, their adverse effects are gastrointestinal, with limited exploration into their impact on mental health.Case presentationThis report examines a 39-year-old male with type 2 diabetes who developed depressive symptoms after starting liraglutide for glycemic control and weight reduction. Symptoms included poor mood, irritability, decreased interest and energy, progressing to sadness, low self-esteem, and physical discomfort. A clinical diagnosis of a depressive episode was made, coinciding with the initiation of liraglutide.Intervention and outcomeThe patient depressive symptoms significantly improved within a week after discontinuing liraglutide and starting antidepressant therapy. This suggests a possible link between liraglutide and depression, despite considering other factors like diabetes-related stress.DiscussionThe report explores potential mechanisms, such as GLP-1RA effects on glucose fluctuations and dopamine modulation, which might contribute to depressive symptoms. The influence on the brain reward system and the reduction in cravings for addictive substances after GLP-1RA use is also discussed as a factor in mood regulation.ConclusionThis case highlights the necessity of being vigilant about potential psychiatric side effects, particularly depression, associated with GLP-1RAs. The rarity of such reports calls for more research to investigate and understand these implications further.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 39-year-old man with type 2 diabetes, a depressive episode with depressive symptoms developed after liraglutide was started.

    In plain wordsIn one man with type 2 diabetes, depression appeared after he started liraglutide. One case cannot show that liraglutide caused it.

    Peptide
    Liraglutide
    Outcome
    IncreaseDepressive symptoms after starting liraglutide
    Study

    n = 1

    Outcome group
    Adverse events · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    A clinical diagnosis of a depressive episode was made, coinciding with the initiation of liraglutide.
    1 context sentence
    Summary · context
    This report examines a 39-year-old male with type 2 diabetes who developed depressive symptoms after starting liraglutide for glycemic control and weight reduction.

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 02HumanNot a test of Liraglutide aloneCase report or seriesSafety outcome

    In the same patient, depressive symptoms improved within a week after liraglutide was stopped and antidepressant therapy was started.

    In plain wordsIn the same man, depression improved within a week after liraglutide was stopped and an antidepressant was started.

    Peptide
    Liraglutide
    Outcome
    DecreaseDepressive symptoms after stopping liraglutide and starting antidepressant
    Study

    n = 1

    Outcome group
    Adverse events · Mental health and mood

    Source sentences

    Summary
    The patient depressive symptoms significantly improved within a week after discontinuing liraglutide and starting antidepressant therapy.
    1 context sentence
    Summary · context
    This report examines a 39-year-old male with type 2 diabetes who developed depressive symptoms after starting liraglutide for glycemic control and weight reduction.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.